(S)-2-(2-methylnaphthalene-6-yl)propanoic acid | 1049682-98-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (S)-2-(2-methylnaphthalene-6-yl)propanoic acid
• 英文别名: (2S)-2-(6-methylnaphthalen-2-yl)propanoic acid
• CAS: 1049682-98-5
• 化学式: C₁₄H₁₄O₂
• 分子量: 214.264
• InChiKey: LJRVHSWMFDDXLN-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (S)-benzhydryl 2-(2-methoxynaphthalen-6-yl)propanoate 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 反应 1.25h， 以83%的产率得到(S)-2-(2-methylnaphthalene-6-yl)propanoic acid
  参考文献：
  名称：

  Convenient Formation of Diphenylmethyl Esters Using Diphenylmethyl Trichloroacetimidate

  摘要：

  Diphenylmethyl trichloroacetimidate is a useful reagent for the protection of carboxylic acids as their corresponding diphenylmethyl esters. These esterifications proceed rapidly without the need for an added catalyst or promoter. A variety of carboxylic acid substrates undergo esterification in excellent yields with the trichloroacetimidate reagent, including substrates possessing acid- or base-sensitive functionality. Protection of a carboxylic acid with a highly enolizable alpha-stereocenter using diphenylmethyl imidate was also accomplished without racemization.

  DOI：

  10.1055/s-0033-1340293

文献信息

• CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING
  申请人：Reiley Pharmaceuticals, Inc.

  公开号：US20150374858A1

  公开（公告）日：2015-12-31

  Conjugates derived from non-steroidal anti-inflammatory drugs (NSAIDs) and methods of use thereof are disclosed, useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The NSAID-based conjugates contain an imaging moiety. The conjugates concentrate at sites of increased cyclooxygenase expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections.

  披露了来自非甾体抗炎药（NSAIDs）的衍生物及其使用方法，这对于识别和定位患者疼痛感觉的病理和/或炎症部位；识别原发、继发、良性或恶性肿瘤的部位；以及诊断感染或确认或排除疑似感染非常有用。基于NSAID的偶联物含有成像基团。这些偶联物在环氧化酶表达增加的部位富集，从而揭示了前列腺素产生增加的部位，这与疼痛和炎症有关，并与肿瘤存在和/或位置有关。识别COX表达增加的区域也有助于筛查感染。
• NAPROXEN-BASED CHIRAL COMPOUNDS AND LIQUID CRYSTAL DISPLAY APPLICATIONS
  申请人：Zhang Yongqiang

  公开号：US20130172558A1

  公开（公告）日：2013-07-04

  Naproxen-based ferroelectric liquid crystal (FLC) or nematic liquid crystal chiral compounds, which can be used in liquid crystal compositions useful for electro-optical and display device applications. The liquid crystal can be a ferroelectric liquid crystal. Also provided is a display device that includes the Naproxen-based ferroelectric liquid crystal (FLC) or nematic liquid crystal chiral compound. Also provided is a method of preparing a liquid crystal display device on silicon that includes incorporating the Naproxen-based ferroelectric liquid crystal (FLC) or nematic liquid crystal chiral compound, into a liquid crystal display on silicon by disposing the compound in a liquid crystal, or the liquid crystal, onto a silicon surface.

  基于萘普生的铁电液晶（FLC）或向列相液晶手性化合物，可用于液晶组合物，适用于电光和显示设备应用。液晶可以是铁电液晶。还提供了包括基于萘普生的铁电液晶（FLC）或向列相液晶手性化合物的显示设备。还提供了一种在硅上制备液晶显示器的方法，该方法包括通过将该化合物置于液晶中或将液晶置于硅表面来将基于萘普生的铁电液晶（FLC）或向列相液晶手性化合物纳入硅上的液晶显示器中。
• Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use
  申请人：——

  公开号：US20020016322A1

  公开（公告）日：2002-02-07

  The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated nonsteroidal antiinflammatory compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The present invention also provides methods for treating, preventing and/or reducing inflammation, pain, and fever; decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of nonsteroidal antiinflammatory drugs; treating and/or preventing gastrointestinal disorders; treating inflammatory disease states and disorders; and treating and/or preventing ophthalmic diseases or disorders.

  本发明描述了新型的亚硝酸化和/或亚硝基化的非甾体抗炎化合物，以及包含至少一种亚硝酸化和/或亚硝基化的非甾体抗炎化合物的新型组合物，以及可选地含有至少一种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物的化合物。本发明还提供了治疗、预防和/或减轻炎症、疼痛和发热的方法；减少或逆转由非甾体抗炎药物使用引起的胃肠道、肾脏和其他毒性；治疗和/或预防胃肠道疾病；治疗炎症性疾病和疾病状态；以及治疗和/或预防眼科疾病或疾病状态。
• Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
  申请人：——

  公开号：US20030207919A1

  公开（公告）日：2003-11-06

  The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated nonsteroidal antiinflammatory compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The present invention also provides methods for treating, preventing and/or reducing inflammation, pain, and fever; decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of nonsteroidal antiinflammatory drugs; treating and/or preventing gastrointestinal disorders; treating inflammatory disease states and disorders; and treating and/or preventing ophthalmic diseases or disorders.

  本发明描述了新型的亚硝酸化和/或亚硝基化非甾体抗炎化合物，以及至少包含一种亚硝酸化和/或亚硝基化非甾体抗炎化合物以及可选地至少一种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物的化合物的新型组合物。本发明还提供了治疗、预防和/或减轻炎症、疼痛和发热的方法；减少或逆转非甾体抗炎药物使用所导致的胃肠道、肾脏和其他毒性；治疗和/或预防胃肠道疾病；治疗炎症性疾病状态和疾病；以及治疗和/或预防眼科疾病或疾病的方法。
• FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE
  申请人：Bezwada Rao S.

  公开号：US20120289614A1

  公开（公告）日：2012-11-15

  This invention relates to the discovery of functionalized triclosan monomers and oligomers that, when incorporated into a substrate of, or applied as part of a coating to, medical devices and/or consumer products may extend the duration of antimicrobial properties to the medical devices and/or consumer products.

  本发明涉及发现的功能化三氯生单体和寡聚物，当它们被纳入医疗设备或消费品的基质中，或作为涂层的一部分应用于医疗设备和/或消费品时，可以延长医疗设备和/或消费品的抗菌性能。